Cancer patient and advocate David Mitchell visited Novartis to discuss what a fair price might be for its CAR-T treatment, but he left disappointed.
The 10 CV drugs we’re profiling here represent the best-sellers by global 2016 sales, excluding those that faced generic competition throughout the year.
A mutual fund that says it lost a mind-boggling $80 billion investing in Valeant alleges in a lawsuit that Valeant was a criminal enterprise.
The forces of competition are mounting against Humira, the world’s best-selling drug at $16 billion in global sales, with approval of a second biosimilar in…
With real-world cardiovascular outcomes, Amgen says Repatha is cost-effective at $9,669 per year.
Pfizer has rebuked U.K. drug cost watchdog NICE for its refusal to recommend approval of the drugmaker's new targeted leukemia treatment.
Sun Pharma has been stung by a decade-old pay-for-delay lawsuit, one of a of a host of issues that contributed to a 74% profit slide.
The generics pricing hit that's slammed Teva shares over last week? The company knew it was coming—and stayed mum for five weeks.
Trump wants to lower the tax burden for companies bringing cash back to the U.S. from overseas, but repatriation may not spur M&A.
After 10 years of shifting pharma fortunes, there's a story behind every revenue tally for Merck, Pfizer, Novartis, Bristol-Myers and their peers.